Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,082 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vision Disorder Clear all
Recruiting No phase listed Observational

Prospective Natural History Study of POLG Disease

NCT07775872
View directory record Official record
Conditions
PolG, Primary Mitochondrial Myopathy
Interventions
Not listed
Lead sponsor
The POLG Foundation
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
7
States / cities
San Diego, California • Aurora, Colorado • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 28, 2026, 1:42 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

NCT00020475
View directory record Official record
Conditions
Extraocular Extension Melanoma, Recurrent Intraocular Melanoma
Interventions
gp100 antigen, interleukin-2, MART-1 antigen, Montanide ISA-51
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Timeline
2001 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 28, 2026, 1:42 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Examining the Effect of Eye Gaze Technology on Children With Cortical Visual Impairment

NCT06067607
View directory record Official record
Conditions
Cortical/Cerebral Visual Impairment, Cerebral Palsy
Interventions
eye gaze technology
Other
Lead sponsor
Rockhurst University
Other
Eligibility
2 Years to 10 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 28, 2026, 1:42 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)

NCT06792500
View directory record Official record
Conditions
MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
Interventions
Glycerol Tributyrate
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 28, 2026, 1:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Efficacy of PEG-400 and Systane Artificial Tears (Alcon) on Quality of Vision

NCT00627302
View directory record Official record
Conditions
Myopia
Interventions
PEG-400, Systane
Drug
Lead sponsor
Bp Consulting, Inc
Network
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Rockville Centre, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2008 · Synced Oct 28, 2026, 1:42 AM EDT
Completed Phase 2 Interventional

Safety and Intraocular Pressure (IOP) Lowering Efficacy of Low Dose Travoprost

NCT00637130
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Travoprost ophthalmic solution, 0.0008%, Travoprost ophthalmic solution, 0.001%, Travoprost ophthalmic solution, 0.0012%, TRAVATAN, Vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Oct 28, 2026, 1:42 AM EDT
Completed Not applicable Interventional Results available

Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves

NCT01883856
View directory record Official record
Conditions
Glaucoma
Interventions
Silicone plate Ahmed Glaucoma Valve (Model FP7), Porous Plate Ahmed Glaucoma Valve (Model M4)
Device
Lead sponsor
Peter Netland, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 28, 2026, 1:42 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Vision In Preschoolers Study (VIP Study)

NCT00038753
View directory record Official record
Conditions
Amblyopia, Strabismus, Refractive Error
Interventions
Vision Screening
Procedure
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
36 Months to 59 Months
Healthy volunteers
Accepts healthy volunteers
U.S. locations
5
States / cities
Berkeley, California • Boston, Massachusetts • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2009 · Synced Oct 28, 2026, 1:42 AM EDT
Withdrawn Phase 4 Interventional

Manuka Eye Droops for Treatment of Allergy

NCT03862053
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Manuka honey
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Germantown, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 28, 2026, 1:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of Motion in Infants' Ability to Categorize

NCT00362076
View directory record Official record
Conditions
Child Development
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Months to 6 Years
Enrollment
941 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 28, 2026, 1:42 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis

NCT00854750
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ACTHAR
Drug
Lead sponsor
Elliot Frohman
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 28, 2026, 1:42 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Optical Defocus to Stimulate Eye Elongation in Hyperopia

NCT00950924
View directory record Official record
Conditions
Hyperopia, Refractive Error
Interventions
Simultaneous Vision Bifocal Soft Contact Lenses, Single Vision Soft Contact Lenses
Device
Lead sponsor
Aller, Thomas A., OD
Other
Eligibility
5 Years to 12 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
San Bruno, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 28, 2026, 1:42 AM EDT
Completed Phase 3 Interventional Results available

A Long-term Safety Study of Once-daily Travatan

NCT00051168
View directory record Official record
Conditions
Glaucoma, Open-angle, Ocular Hypertension
Interventions
Travatan
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2011 · Synced Oct 28, 2026, 1:42 AM EDT
Terminated Phase 1Phase 2 Interventional

Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration

NCT00712491
View directory record Official record
Conditions
Age-related Macular Degeneration, Choroidal Neovascularization
Interventions
Sirolimus
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 28, 2026, 1:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Smartphone-based Utility of the Vestibulo-ocular Reflex

NCT06856746
View directory record Official record
Conditions
Vestibulo-Ocular Reflex (VOR) Dysfunction, Vestibular Function Tests, Vestibular Function Disorder, mHealth Application
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 28, 2026, 1:42 AM EDT
Completed Phase 3 Interventional

SOLX Titanium Sapphire Laser for Trabeculoplasty

NCT00145535
View directory record Official record
Conditions
Glaucoma, Glaucoma, Open Angle
Interventions
SOLX Titanium Sapphire Laser (TiSaLT), Argon Laser Trabeculoplasty (ALT)
Device
Lead sponsor
SOLX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
5
States / cities
Petaluma, California • Tampa, Florida • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2010 · Synced Oct 28, 2026, 1:42 AM EDT
Terminated Not applicable Interventional

Safety and Effectiveness of the Hydrus Microstent

NCT05198297
View directory record Official record
Conditions
Open Angle Glaucoma, Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma, Pigmentary Glaucoma
Interventions
Hydrus Microstent, Ophthalmic surgery
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
45 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Bentonville, Arkansas • Zephyrhills, Florida • Fraser, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 28, 2026, 1:42 AM EDT
Completed No phase listed Observational

Prevalence of Visual Dysfunction in Neurological Disorders

NCT04836715
View directory record Official record
Conditions
Parkinson Disease, Other Neurological Disorders, Healthy
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
92 participants
Timeline
2021 – 2023
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 28, 2026, 1:42 AM EDT
Completed No phase listed Observational Results available

A Prospective Observational Study of Adult Strabismus

NCT02510040
View directory record Official record
Conditions
Convergence Insufficiency, Divergence Insufficiency, Hypertropia
Interventions
Prism, Orthoptic Exercises, Eye Muscle Surgery, Botox Injection
Device · Other · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 28, 2026, 1:42 AM EDT
Completed Not applicable Interventional

Safety and Feasibility of the ELIOS System in POAG Patients

NCT05999006
View directory record Official record
Conditions
Glaucoma, Primary Open Angle
Interventions
ELIOS Procedure
Device
Lead sponsor
Elios Vision, Inc.
Industry
Eligibility
45 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Glendale, Arizona • Rock Island, Illinois • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 28, 2026, 1:42 AM EDT
Terminated Phase 3 Interventional Results available

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery

NCT01298752
View directory record Official record
Conditions
Inflammation, Pain, Cataract
Interventions
Mapracorat, Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 28, 2026, 1:42 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain

NCT02793817
View directory record Official record
Conditions
Post Surgical Ocular Inflammation and Pain
Interventions
KPI-121 1% Ophthalmic Suspension dosed BID, Vehicle of KPI-121 Ophthalmic Suspension dosed BID
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
35
States / cities
Chandler, Arizona • Phoenix, Arizona • Artesia, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 28, 2026, 1:42 AM EDT
Recruiting No phase listed Observational

Cerebral/ Cortical Visual Impairment: Screening, Identification and Outcome Prediction in Neonates

NCT07275021
View directory record Official record
Conditions
Preterm Less Than 32wks With IVH, WMI/PVL, Late Preterm or Term (37-42wks) With Neonatal Encephalopathy Treated With Hypothermia for HIE
Interventions
Prospective Clinical and Neurodevelopmental Data Collection
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
31 Weeks to 42 Weeks
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 28, 2026, 1:42 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

NCT00572455
View directory record Official record
Conditions
Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions
PF-04217329 - Lowest Dose, PF-04217329 - Low Dose, PF-04217329 - Middle Dose, PF-04217329 - High Middle Dose, PF-04217329 - High Dose, PF-4217329 - Highest Dose, PF-04217329 - Vehicle, Latanoprost Vehicle, Latanoprost 0.005%
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
23
States / cities
Artesia, California • Newport Beach, California • Petaluma, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 28, 2026, 1:42 AM EDT